Aug 11, 2025
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease
Jul 31, 2025
Novartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-line use
Jul 03, 2025
Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)
Mar 25, 2025
Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis
Jan 28, 2025
Early detection is a game changer: Novartis makes bold play to prioritize breast health and inspire a new wave of breast cancer screenings
Dec 10, 2024
Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer
Oct 26, 2024
Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial
Oct 24, 2024
Novartis ribociclib (Kisqali®) recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
Sep 17, 2024
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
May 25, 2024
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio
May 25, 2024
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
Apr 17, 2024
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment-naïve people with relapsing multiple sclerosis
Apr 15, 2024
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
Apr 06, 2024
New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting
Feb 16, 2021
Novartis Entresto® granted expanded indication in chronic heart failure by FDA
Dec 09, 2020
Novartis Kisqali® demonstrates nearly five years median overall survival in metastatic breast cancer
Dec 07, 2020
Novartis and Amgen partner with Karamo Brown to support and empower people living with migraine
Dec 01, 2020
Novartis announces FDA approval of Xolair® (omalizumab) for adults with nasal polyps
Nov 19, 2020
New data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseases
Nov 13, 2020
New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17, regardless of age and gender